developing lsc-targeting agents in aml: progress and current therapeutic capacity
Published 3 months ago • 117 plays • Length 0:59Download video MP4
Download video MP3
Similar videos
-
3:04
applying molecular understanding of dlbcl to management strategies
-
3:58
phase ib/iia study of azd4573 acalabrutinib in r/r dlbcl
-
0:48
integrating data to improve cbcl diagnosis
-
1:35
update on phase i study of plamotamab in r/r nhl
-
1:09
the changing role of allosct in dlbcl in the era of novel agents
-
1:28
phase i study of pevonedistat and ibrutinib in r/r b-nhl
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
3:13
targeting cd38 with a bispecific antibody to treat r/r aml: a phase i trial
-
6:16
overview of novel restore and target treatment approach to classical hodgkin lymphoma
-
1:45
ham-ven as salvage treatment for r/r aml: results from the sal-relax trial
-
1:13
utilizing pet/ct to improve staging in extranodal marginal zone lymphoma
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:16
predictors of long-term survival in patients with dlbcl/hgbcl following autosct
-
2:40
primary analysis of the phase iii transform study: liso-cel in second-line lbcl
-
0:42
targeted therapies for dlbcl treatment
-
5:35
clinical and prognostic significance of aberrant t-cell marker expression in aml
-
1:27
improving ttd for cbcl
-
1:27
tp53-aberrant mcl: challenges and treatment approaches